Exercise to enhance chemoradiotherapy effectiveness in advanced rectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This feasibility study involves a single arm approach where patients diagnosed with locally advanced rectal cancer will participate in an 11-week structured exercise program consisting of vigorous intensity aerobic interval exercise and resistance training. The program is designed to be implemented before, during, and after their neoadjuvant chemoradiotherapy treatment. A total of 30 patients will be recruited from Castle Hill Hospital, and their progress will be monitored over a 6-month follow-up period post-treatment. The study aims to assess the impact of exercise on the efficacy of chemoradiotherapy in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or older
* Have been diagnosed with locally advanced rectal cancer using MRI (Magnetic Resonance Imaging) and histological finding
* Have been offered long-course neoadjuvant chemoradiotherapy in the Queens Centre, Castle Hill Hospital
* Willing and able to comply with all study requirements
* Able and willing to voluntarily give informed consent to take part.

Exclusion Criteria:

* Inability to understand basic written and spoken English, as research materials will all be written in English.
* Any movement deficiencies limiting ability to engage in exercise.
* Impaired cognition and/or capacity limiting ability to provide informed consent.
* Cardiovascular and/or cardiopulmonary conditions that will impede ability to safely perform exercise.
* Severe psychiatric disorders.
* With any other health condition which oncologists and research team agrees will impede ability to safely perform exercises.
* Presence of metastatic cancer.

Where it's running

• Castle Hill Hospital
  Cottingham, East Yorkshire, United Kingdom Recruiting

Study contacts

• Study coordinator: Chizitara Amadi
• Email: CHIZITARA.AMADI-2021@hull.ac.uk
• Phone: 07887391904

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Triplet vs doublet induction therapy with chemoradiotherapy for high-risk locally advanced rectal cancer, followed by surgery or watch-and-wait

  This trial tests whether a triplet induction chemotherapy (FOLFOXIRI) before chemoradiotherapy improves response and long-term outcomes in high-risk locally advanced rectal cancer compared with a doublet induction (CAPOX/FOLFOX).

  Recruiting at 10 sites Phase 3 Catharina Ziekenhuis Eindhoven · Arnhem, Gelderland and 19 other locations · NCT07472868

• Adding modulated electro‑hyperthermia to total neoadjuvant therapy for locally advanced rectal cancer

  This trial tests whether adding modulated electro‑hyperthermia (mEHT) to total neoadjuvant therapy helps adults with locally advanced rectal cancer achieve more tumor down‑staging and higher rates of complete pathological response.

  Recruiting Phase 3 Dalin Tzu Chi General Hospital · Chiayi City, Dalin Township · NCT07372300

• Combining chemoradiotherapy with immunotherapy for advanced rectal cancer

  This study is testing whether adding an immunotherapy drug to standard treatment can help people with advanced rectal cancer feel better and improve their quality of life.

  Recruiting at 2 sites Phase 2/3 Beijing Friendship Hospital · Beijing, Beijing Municipality and 1 other locations · NCT06312982

• Comparing two methods for preserving organs in rectal cancer patients

  This study is testing two different ways to treat rectal cancer in patients who responded well to initial treatment, to see which method helps them keep their organs and improve their quality of life.

  Recruiting at 7 sites The Netherlands Cancer Institute · Nijmegen, Gelderland and 6 other locations · NCT05772923

• Neoadjuvant treatment for locally advanced rectal cancer using Serplulimab, CAPEOX, and Celecoxib

  This study is testing a new treatment combining an immune therapy and chemotherapy to see if it can help people with locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT05731726

• Using circulating tumor DNA to guide treatment for advanced rectal cancer

  This study is testing if using a blood test to check for tumor DNA can help doctors give better treatment to people with advanced rectal cancer by personalizing their therapy based on their risk of recurrence.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05601505

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.